Search

Displaying results 5021 - 5030 of 5925 in total
  1. Drug

    Amenamevir

    go.drugbank.com/drugs/DB11701
    Investigational

    Amenamevir has been used in trials studying the treatment of Herpes Zoster, Herpes Simplex, Herpes Genitalis, and Safety of Amenamevir.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  2. Drug

    Talinolol

    go.drugbank.com/drugs/DB11770
    Investigational

    Talinolol has been investigated for the basic science of Gastrointestinal Motility Disorder.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  3. Drug

    Pazufloxacin

    go.drugbank.com/drugs/DB11774
    Investigational

    Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  4. Drug

    Allicin

    go.drugbank.com/drugs/DB11780
    Investigational

    Allicin has been used in trials studying the treatment of Follicular Lymphoma.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A Inhibitors
  5. Drug

    Relugolix

    go.drugbank.com/drugs/DB11853
    ApprovedInvestigational

    Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  6. Drug

    Valspodar

    go.drugbank.com/drugs/DB11869
    Investigational

    Valspodar has been used in trials studying the treatment of Cancer, Sarcoma, Leukemia, Lymphoma, and Breast Cancer, among others.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  7. Drug

    6-O-benzylguanine

    go.drugbank.com/drugs/DB11919
    Investigational

    6-O-benzylguanine has been used in trials studying the treatment of HIV Infection, Adult Gliosarcoma, Adult Glioblastoma, Stage I Adult Hodgkin Lymphoma, and Stage II Adult Hodgkin Lymphoma, among others.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  8. Drug

    Dacomitinib

    go.drugbank.com/drugs/DB11963
    ApprovedInvestigational

    Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain o...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  9. Drug

    Binimetinib

    go.drugbank.com/drugs/DB11967
    ApprovedInvestigational

    Binimetinib, also known as Mektovi, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with Encorafenib. On June 27, 2018, the Food and Drug Administration approved the combination o...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  10. Drug

    Ponesimod

    go.drugbank.com/drugs/DB12016
    ApprovedInvestigational

    Ponesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-ph...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates